AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research
The AACR and the Prevent Cancer Foundation are pleased to co-sponsor this major international Award in recognition of outstanding cancer prevention research.
The AACR and the Prevent Cancer Foundation are pleased to co-sponsor this major international Award in recognition of outstanding cancer prevention research. The AACR-Prevent Cancer Foundation Award for Excellence in Cancer Prevention Research is given to a scientist residing in any country in the world for his or her seminal contributions to the field of cancer prevention. Such investigations must have been conducted in basic, translational, clinical, epidemiological, or behavioral science in cancer prevention research. Further, these studies must have had not only a major impact on the field, but must also have stimulated new directions in this important area.
The recipient of the Award will receive a $5,000 honorarium and present a 50-minute lecture at the 8th Annual AACR International Conference on Frontiers in Cancer Prevention Research. The Conference will be held December 6-9, 2009, at the Hilton Americas, Houston, TX.
The nomination deadline is Friday, July 31, 2009.
For more information: http://www.aacr.org/home/scientists/scientific-achievement-awards/prevent-cancer-award.aspx
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
!["This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population," according to the study authors.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F6934d676a539495d8b2109e4b3762700aa723bf3-1200x873.jpg%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=75 "\"This [network meta-analysis] demonstrated for the first time that [anlotinib/benmelstobart plus chemotherapy] is the most efficacious regimen for extending survival in ES-SCLC, highlighting its potential as a preferred first-line treatment option for this patient population,\" according to the study authors.")
